Prognostic role of plasminogen-activator-inhibitor-1 levels in treatment with streptokinase of patients with acute myocardial infarction

Clinical Cardiology

Volumn 23, Issue 7, 2000, Pages 486-489

  Sinkovič, Andreja ^a  

^a UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

Author keywords

Acute myocardial infarction; Plasminogen activator inhibitor type 1; Streptokinase

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HEART REINFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; REPERFUSION; TREATMENT OUTCOME;

EID: 0033948352     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960230723     Document Type: Article

References (19)

1. Fuster V, Badimon L, Cohen M, Abose JA, Badimon JJ, Chesebro J: Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988;77(6):1213-1220
2. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group: Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-322
3. Coller BS: Platelets and thrombolytic therapy. N Engt J Med 1990;322:33-42
4. Fujii S, Abendschein DR, Sobel BE: Augmentation of plasminogen activator inhibitor type 1 activity in plasma by thrombosis and by thrombolysis. J Am Coll Cardiol 1991;18:1547-1557
5. Fujii S, Hopkins WE, Sobel BE: Mechanisms contributing to increased synthesis of plasminogen activator inhibitor type 1 in endothelial cells by constituents of platelets and their implications for thrombolysis. Circulation 1991;83:645-651
6. Levi M, Biemond B, van Zonnenweld AJ, ten Cate JW, Pannekoek H: Inhibition of plasminogen-activator-inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992;85:305-312
7. Gray RP, Yudkin YS, Patterson DL: Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: A role for plasminogen activator inhibitor? Br Heart J 1993;70:530-536
8. Sane DC, Stump DC, Topol EJ, Sigman KN, Kereiakis DJ, George BS, Mantell SJ, Macy E, Collen D, Califf R: Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction. Thromb Haemost 1991;65:275-279
9. Aimer LO, Ohlin H: Elevated levels of the rapid inhibitor of plasminogen activator (t-PAI) in acute myocardial infarction. Thromb Res 1987;47:335-339
10. Barbash GI, Hod H, Roth A, Miller HI, Rath S, Zahav YH, Modan M, Zivelin A, Laniado S, Seligsohn U: Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1989;64:1231-1235
11. Dawson S, Henney A: The status of PAI-1 as a risk factor for arterial and thrombotic disease: A review. Atherosclerosis 1992;95: 105-117
12. Sinkovič A: Pretreatment plasminogen-activator-inhibitor-1 (PAI-1) levels and the outcome of thrombolysis with streptokinase in patients with acute myocardial infarction. Am Heart J 1998;136: 406-411
13. White HD: Selecting a thrombolytic agent. Cardiol Clin 1995;13: 347-354
14. Bull. S.S.C.C./S.G.K.C. enzymes supplement 1982;23:5.
15. Hamsten A, Wiman B, de Faire U, Bombaeck M: Increased plasma levels of rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engt J Med 1985;313: 1557-1563
16. Hamsten H, de Faire U. Walldius G, Dahlen G, Szanosi A, Landou C, Blombaeck M, Wiman B: Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987;II:3-9
17. Schroeder R, Wegscheider K, Schroeder K, Dissman R, Mayer-Sabellik W: Extent of early ST-segment elevation resolution: A strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A Substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) Trial. J Am Coll Cardiol 1995;26: 1657-1664
18. The GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682
19. van Loon P, Rijkan DC, Bronmer EJP, van der Maas APC: The amount of plasminogen, tissue type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemost 1992;67:101-105